

New therapeutic targets in the inflammatory microenvironment



CrossMark

Eric Tartour

To cite: Tartour E. New therapeutic targets in the inflammatory microenvironment. *ESMO Open* 2018;3:e000310. doi:10.1136/esmoopen-2017-000310

Department of Immunology,
Hôpital Européen Georges
Pompidou, Paris, France

Correspondence to
Professor Eric Tartour; eric.tartour@aphp.fr

[Click here to listen to the Podcast](#)

The introduction of immune checkpoint inhibitors introduced a new era of oncology. The CTLA4 or PD1/PDL1 axis targeting immune checkpoint inhibitors has shown remarkable and long-lasting responses in a variety of tumour types. Here, the biology of immune checkpoint inhibitors is outlined including the main site of action for the different immune checkpoint inhibitor types. Further, other possible immune checkpoints like LAG3 and other cells types including macrophages and NK cells, as future directions for immune modulating therapies, are discussed. Combination approaches, including immune checkpoint inhibitors and

chemotherapy or radiotherapy, are currently investigated for their synergistic efficacy, and preliminary data have shown promising results.

Provenance and peer review Not commissioned; internally peer reviewed.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

© European Society for Medical Oncology (unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.